Leonhardt Adds HIF-1 Alpha To Estate of Bioelectric Controlled Release Regenerative Proteins


Salt Lake City, Utah andSanta Monica, CA June8th, 2017(PRBUZZ)— Leonhardt's Launchpads, an organ regenerationand recoveryfocused innovation/startup acceleratortoday announced that it has filed a new patent applicationclaimfor the controlled expression ofHypoxia Inducible Factor 1 (HIF 1 Alpha). HIF 1 Alpha is a powerful organ regeneration protein. This patent will be sub-licensed exclusively organ by organ to 26 unique organ regeneration focused startups within the Leonhardt led innovation accelerators in Utah and California including BioLeonhardt heart, AortaCell aorta,RegenaLung lung regeneration,CerebraCell brain, EyeCell eye, Stem Cell Bra breast and PancreaCell for pancreas regeneration.

In recent studies at Leonhardt's own research lab space at BioInnovations Gateway in Utah the team achieved more than 286% increase of HIF-1 Alpha on demand in test article tissues with a specific bioelectric signal.

'We targeted the discovery search for the precise bioelectric signal for triggeringHIF-1 alphaexpression from tissues more than 4 years ago and were delighted to finally hit on it with a highly substantial expression increase with our optimized signal. This adds to our building library of overfifteenbioelectric stimulation signals for promoting organ regeneration. We believe this combined with our programmable micro-infusion pump and fifteen component organ regeneration composition puts our team in a leadership position to in the near future help patients with degenerating and diseased organs to recover.Dr. Jorge Genoveseco-Inventor, VP of Bioelectric Regeneration Research,BioLeonhardt LTP,Leonhardt's Launchpads byCal-X Stars Business Accelerator, Inc. and Leonhardt's Launchpads Utah, Inc.

The Leonhardt-Genovese team working in collaboration with component suppliers has developed both wireless non-invasive and implantable wire lead based means to get their regeneration and healing promoting bioelectric signals totargetorgans.

Hypoxia has been proven as a critical element in the organ regeneration process. Hypoxia Inducible Factor(HIF-1a) is a master regulator of the adaptative response to hypoxia.HIF-1a over expressionin cellsmimicsthe mechanisms triggered by hypoxiain injured or diseased tissuesand increasestheir therapeutic potential withoutdirecthypoxia stimulation.

HIF-1AlphaPotential UsefulProperties for Organ Regeneration:

HIF 1asignalingpromotes heart regeneration.
HIF 1asignalingreduces infarction size and attenuates cardiac dysfunction.
HIF1ainduces coronary collateral vessel formation.
HIF 1aisa tumor suppressor.
HIF 1a has been reported a gateway controller of cancer.
HIF 1a promotesliver regeneration.
HIF 1a promotes lung regeneration via aveolar development.
HIF 1a promotes brain saving following traumatic brain injury or stroke.
HIF 1apromotes retinal eye regeneration.
HIF 1a management seems to be important to healthy kidney function and can protect against kidney injury.
HIF 1a helps promote muscle regeneration.
HIF 1a helps promote wound healing.
HIF 1a has a supportive role in hair regeneration.
HIF 1a promotes extracellular matrix.
HIF 1a has a critical role in bone development and healing.
HIF 1a may be important to stabilize teeth positions after accelerated tooth movement.
HIF 1ais an essential regulator of inflammation.

Note - All above safety and efficacy claims, if any, mentioned above are yet to be be confirmed in randomized, placebo controlled clinical studies.

'HIF 1Alphais one of the most potent growth factors in promoting cell, tissue and organ repair applicable to a wide variety of uses. It has been demonstrated to be especially useful in heart regeneration. We are proud to have extended our portfolio of bioelectrical stimulation signals to includeHIF 1 Alpha. We are embarking upon well controlled translation research studies to prove our combination therapy out for regenerative repair of a number of organs.states Dr. Leslie Miller, Chief Medical Officer of Leonhardt's Launchpads, Second Heart Assist, Inc.and BioLeonhardt.

About Leonhardt's Launchpads:
Operated by Cal-X Stars Business Accelerator, Inc. Leonhardt's Launchpads was founded in Santa Monica in 2013. The five year accelerator is incubating 26 regenerative medtech and 4 regenerative economy startups and licensable technology platforms (LTPs).Leonhardt's Launchpads also manages a smaller incubator/accelerator at the University of Northern California Science and Technology Innovation Center (UNC STIC) in Petaluma, CA since 2008.

About Leonhardt's Launchpads Utah, Inc.:
Founded in November 2015 in Salt Lake City, Utah, just off the campus of the University of Utah, is the World's First Organ Regeneration Focused Innovation/Startup Accelerator. The company has lab space with a staffed research team at the USTAR BioInnovations Gateway Utah facility at 2500 S. State Street, Salt Lake City, Utah. The accelerator is currently incubating more than a dozenorgan regenerationand recoveryfocused startupsat this time.

About Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures):
Founded in 1982 is the patent holding vehicle and venture capital arm of inventor Howard J. Leonhardt. In the 1980's Leonhardt developed a market leading cardiovascular balloon catheter, in the 1990's the leading stent graft system for aortic aneurysm repair and one of the first percutaneous heart valves and biological pacemakers. Since 2000 the focus has been on organ regeneration technologies with a combination of bioelectric signaling and repeat delivery of mixed stem cell + growth factor based compositions. Leonhardt has over 21 U.S. Patents with over 100 issued patent claims and dozens more pending.

About BioLeonhardt:
BioLeonhardt LTP founded in 2013 is the flagship technology platform of Leonhardt Ventures and Leonhardt's Launchpads Utah, Inc. focused on heart regeneration. BioLeonhardt developed a combination three component system for heart regeneration comprised of (1) a bioelectric stimulator controlling release of regenerating promoting proteins including a stem cell homing factor, (2) an implantable, programmable and re-fillable micro infusion pump and (3) a fifteen component stem cell based heart regeneration composition.

Cautionary Note Regarding Forward-Looking Statements:
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Cal-X Stars Business Accelerator, Inc, Leonhardt Vineyards LLC DBA Leonhardt Ventures, or Leonhardt's Launchpads Utah, Inc. management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'believes, 'plans, 'could, 'anticipates, 'expects, 'estimates, 'should, 'target, 'will, 'would and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our 506D part C Cal-X Stars Businesss Accelerator, Inc. private placement memorandum originally filed in 2013 and updated via our Annual Reports. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
Note Each organ specific web site linked via Leonhardt Ventureswww.leonhardtventures.comhas at the bottom or the tope of its landing page a link to supporting scientific articles.

Web Sites:
Leonhardt Ventureswww.leonhardtventures.com this site includes links to all portfolio startups.
BioLeonhardt LTPwww.bioleonhardt.com
Cal-X Stars Businesss Accelerator, Inchttp://calxstars.com/what-we-do/includes links to videos of platform innovations.
Leonhardt's Launchpads Utah, Inc.http://leonhardtventures.com/leonhardts-launchpads-utah/

Leonhardt's Launchpads by Cal-X Stars,2000 Main Street, Unit 333, Santa Monica, CA 90405 -www.leonhardtventures.com+www.calxstars.com

Leonhardt's Launchpads Utah, Inc.370 S, 300 E, Salt Lake City, UT 84111
Research Lab @ 2500 S State St. #224, Salt Lake City, UT 84115
Contact: Howard Leonhardt email

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.